Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1358762/000156459018020473/reta-10q_20180630.htm
August 2022
July 2022
June 2022
May 2022
March 2022
February 2022
February 2022
November 2021
October 2021
August 2021
Exhibit 99.1
|
|
REATA PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND AN UPDATE ON DEVELOPMENT PROGRAMS
IRVING, Texas—August 8, 2018
—Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today provided an update on the Company's product development programs and announced financial results for the second quarter ended June 30, 2018.Product Development Updates
Bardoxolone Methyl in Rare Forms of Chronic Kidney Disease
In July, we reported positive one-year results for the Phase 2 portion of CARDINAL, a study of bardoxolone methyl (bardoxolone) in patients with chronic kidney disease (CKD) due to Alport syndrome, and positive final results for the Phase 2 autosomal dominant polycystic kidney disease (ADPKD) cohort of PHOENIX. In the Phase 2 portion of CARDINAL, bardoxolone produced a statistically significant improvement in estimated glomerular filtration rate (eGFR) of 10.4 mL/min/1.73 m2 (p<0.0001) after 48 weeks of treatment and 4.1 mL/min/1.73 m2 (p<0.05) at Week 52 after withdrawal of active drug for four weeks (the retained eGFR benefit). Reata collected historical eGFR data for 22 out of the 25 Phase 2 study patients. The historical eGFR data demonstrate that the Phase 2 study patients’ kidney function was declining at an average annual rate of 4.2 mL/min/1.73 m2 for three years prior to study entry. The demonstration of a retained eGFR benefit in patients with Alport syndrome suggests that bardoxolone may delay or prevent kidney failure in these patients and that the Phase 3 portion of CARDINAL is conservatively powered with respect to the key secondary endpoint of retained eGFR benefit. Enrollment in the Phase 3 portion of CARDINAL is proceeding as planned, and top-line data is expected to be available in the second half of 2019.
In May 2018, the European Commission granted Orphan Drug designation for bardoxolone for the treatment of Alport syndrome. Bardoxolone previously received Orphan Drug designation for the treatment of Alport syndrome from the FDA.
In the Phase 2 ADPKD cohort of PHOENIX, bardoxolone produced a statistically and clinically significant, time-dependent increase in eGFR of 9.3 mL/min/1.73 m2 (p<0.0001) at Week 12, which was the primary endpoint of the study. Reata collected historical eGFR data for 29 of the 31 Phase 2 study patients. The historical eGFR data demonstrate that these patients’ kidney function was declining at an average annual rate of 4.8 mL/min/1.73 m2 for three years prior to study entry. In other forms of CKD, changes in eGFR at Week 12 produced by bardoxolone significantly correlated with eGFR change after one year of treatment, which suggests that long-term eGFR improvements and retained eGFR benefit observed in other forms of CKD may translate to patients with ADPKD. Reata is currently developing plans to advance the ADPKD program into a pivotal Phase 3 trial.
Enrollment in the IgA nephropathy and type 1 diabetic CKD (T1D CKD) cohorts of PHOENIX was completed in the second quarter, and we expect full primary endpoint data from these cohorts to be available during the third quarter of
1
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1358762/000156459018020473/reta-10q_20180630.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Reata Pharmaceuticals Inc.
Reata Pharmaceuticals Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:
Rating
Learn More![]()
If we incur indebtedness, we could become subject to covenants that would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell, or license intellectual property rights, and other operating restrictions that could adversely affect our ability to conduct our business, and any such debt could be secured by some or all of our assets.
The increase in investment income for the three months ended June 30, 2018, compared to the three months ended June 30, 2017, was due to investment and interest income earned on cash equivalents.
The increase in investment income for the six months ended June 30, 2018, compared to the six months ended June 30, 2017, was due to investment and interest income earned on cash equivalents.
We have also incurred increased expenses associated with being a public company, including exchange listing and SEC requirements, director and officer insurance premiums, legal, audit, and tax fees, regulatory compliance programs, and investor relations costs.
Through June 30, 2018, we have raised gross cash proceeds of $476.6 million through the sale of convertible preferred stock and received $750 million from payments under license and collaboration agreements, $169.8 million in net proceeds from our IPO and follow-on offering of our Class A common stock, and $77.3 million in net proceeds from our Restated Agreement and Loan Agreement.
The increase in the ratio...Read more
The increase in the ratio...Read more
We anticipate that we will...Read more
The increase was primarily due...Read more
Effective July 23, 2018, the...Read more
Per the PGIC, 78% of...Read more
Per the PGIC, 77% of...Read more
However, we anticipate opportunistically raising...Read more
Data suggest that the long-term...Read more
In clinical trials, treatment with...Read more
Other revenue decreased by $0.2...Read more
Clinically meaningful improvements in kidney...Read more
We have observed favorable activity...Read more
License and milestone revenue increased...Read more
Net cash used in operating...Read more
Any of these events could...Read more
The financial terms of these...Read more
This improvement represents approximately two...Read more
General and administrative expenses increased...Read more
General and administrative expenses increased...Read more
Our other research and development...Read more
Costs for certain development activities...Read more
On July 27, 2018, the...Read more
This improvement represents at least...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Material Contracts, Statements, Certifications & more
Reata Pharmaceuticals Inc provided additional information to their SEC Filing as exhibits
Ticker: RETA
CIK: 1358762
Form Type: 10-Q Quarterly Report
Accession Number: 0001564590-18-020473
Submitted to the SEC: Wed Aug 08 2018 4:11:49 PM EST
Accepted by the SEC: Wed Aug 08 2018
Period: Saturday, June 30, 2018
Industry: Pharmaceutical Preparations